PMN Madge K Shafmaster buys $75K worth of shares
Sep 24, 2024, 11:33 PM
-27.83%
What does PMN do
ProMIS Neurosciences, based in Toronto, develops precision medicine for neurodegenerative diseases, focusing on antibody therapeutics targeting misfolded proteins. The company went public on April 3, 2017, and employs six full-time staff.
Madge K Shafmaster bought 60,000 shares of PMN on 20 September at $1.25 per share, worth a total of $75K. They now own 68,333 PMN shares, or a 720% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.